Targets › GNA11
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Oct 2027.
Guanine nucleotide-binding proteins (G proteins) function as transducers downstream of G protein-coupled receptors (GPCRs) in numerous signaling cascades. The alpha chain contains the guanine nucleotide binding site and alternates between an active, GTP-bound state and an inactive, GDP-bound state. (UniProt, P29992)
Open in Phaseline: the race on GNA11, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Novartis | DYP688 GNAQ/GNA11 inhibitor | GNAQ, GNA11 | Phase 1 | Metastatic Uveal Melanoma | Oct 2027 |
Metastatic Uveal Melanoma (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.